open access

Vol 72, No 6 (2014)
Expert consensus statement
Published online: 2014-06-11
Get Citation

Role of echocardiography in monitoring of cardiac toxicity of cancer pharmacotherapy. Expert consensus statement of the Polish Clinical Forum for Cardiovascular Imaging

Grzegorz Piotrowski, Rafał Gawor, Zenon Gawor, Sebastian Szmit, Jarosław D. Kasprzak, Zbigniew Miśkiewicz, Grzegorz Opolski, Adam Torbicki, Maciej Krzakowski, Krzysztof J. Filipiak, Andrzej Szyszka, Edyta Płońska-Gościniak, Polskie Kliniczne Forum Obrazowania Serca i Naczyń
DOI: 10.5603/KP.2014.0126
·
Kardiol Pol 2014;72(6):558-575.

open access

Vol 72, No 6 (2014)
Expert consensus statement
Published online: 2014-06-11

Abstract

Recent oncology development results in significant reduction of morbidity and mortality of several kinds of cancer. Such great achievements are at the cost of frequent cardiotoxicity, which predominantly is manifested as cardiomyopathy, cardiac dysfunction and heart failure (HF). Cardiotoxicity may manifest early — during treatment or late — after treatment completion. There are type 1 — anthracycline-related and type 2 — trastuzumab-related cardiotoxicity. Early detection of cardiotoxicity is crucial for preventing late heart dysfunction and HF. Baseline echocardiographic assessment should be performed in every patient before initiation of cancer treatment and serial monitoring of cardiac safety by means of echocardiography is recommended. The most widely used for this purpose is left ventricular ejection fraction (LVEF) calculated by Simpson’s method with 2 dimensional transthoracic echocardiography. LVEF has numerous limitations, among which significant inter- and intraobserver variability, late decrease of LVEF with its often irreversibility are the most important. Noncontrast 3 dimesional echocardiography is the most reproducible technique for LVEF measurement. Newer echocardiographic technique — myocardial strain imaging has the potential to detect early subclinical cardiac dysfunction due to cardiotoxicity and may be used for the prediction of LV dysfunction. The role of other echocardiographic parameters, particularly of LV diastolic function has not been exactly defined in literature. The decision on discontinuation or modification of cancer therapy should be based on 2 improper, separate measurements of particular echocardiographic parameter or better more than 1 improper parameter should be taken into account. After completion of cancer treatment, echocardiography follow-up is recommended to detect late cardiotoxicity.

Abstract

Recent oncology development results in significant reduction of morbidity and mortality of several kinds of cancer. Such great achievements are at the cost of frequent cardiotoxicity, which predominantly is manifested as cardiomyopathy, cardiac dysfunction and heart failure (HF). Cardiotoxicity may manifest early — during treatment or late — after treatment completion. There are type 1 — anthracycline-related and type 2 — trastuzumab-related cardiotoxicity. Early detection of cardiotoxicity is crucial for preventing late heart dysfunction and HF. Baseline echocardiographic assessment should be performed in every patient before initiation of cancer treatment and serial monitoring of cardiac safety by means of echocardiography is recommended. The most widely used for this purpose is left ventricular ejection fraction (LVEF) calculated by Simpson’s method with 2 dimensional transthoracic echocardiography. LVEF has numerous limitations, among which significant inter- and intraobserver variability, late decrease of LVEF with its often irreversibility are the most important. Noncontrast 3 dimesional echocardiography is the most reproducible technique for LVEF measurement. Newer echocardiographic technique — myocardial strain imaging has the potential to detect early subclinical cardiac dysfunction due to cardiotoxicity and may be used for the prediction of LV dysfunction. The role of other echocardiographic parameters, particularly of LV diastolic function has not been exactly defined in literature. The decision on discontinuation or modification of cancer therapy should be based on 2 improper, separate measurements of particular echocardiographic parameter or better more than 1 improper parameter should be taken into account. After completion of cancer treatment, echocardiography follow-up is recommended to detect late cardiotoxicity.

Get Citation

Keywords

cardiotoxicity, cardioncology, echocardiography, strain imaging, left ventricular ejection fraction, anthracyclines

About this article
Title

Role of echocardiography in monitoring of cardiac toxicity of cancer pharmacotherapy. Expert consensus statement of the Polish Clinical Forum for Cardiovascular Imaging

Journal

Kardiologia Polska (Polish Heart Journal)

Issue

Vol 72, No 6 (2014)

Pages

558-575

Published online

2014-06-11

DOI

10.5603/KP.2014.0126

Bibliographic record

Kardiol Pol 2014;72(6):558-575.

Keywords

cardiotoxicity
cardioncology
echocardiography
strain imaging
left ventricular ejection fraction
anthracyclines

Authors

Grzegorz Piotrowski
Rafał Gawor
Zenon Gawor
Sebastian Szmit
Jarosław D. Kasprzak
Zbigniew Miśkiewicz
Grzegorz Opolski
Adam Torbicki
Maciej Krzakowski
Krzysztof J. Filipiak
Andrzej Szyszka
Edyta Płońska-Gościniak
Polskie Kliniczne Forum Obrazowania Serca i Naczyń

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Sp. z o.o. VM Group Sp.k., ul. Świętokrzyska 73 , 80–180 Gdańsk, Poland

phone:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl